Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials.

ABSTRACT:

Introduction

Disparities in relapse and survival from high-risk neuroblastoma (HRNBL) persist among children from historically marginalized groups even in highly standardized clinical trial settings. Research in other cancers has identified differential treatment toxicity as one potential underlying mechanism. Whether racial and ethnic disparities in treatment-associated toxicity exist in HRNBL is poorly understood.

Methods

This is a retrospective study utilizing a previously assembled merged cohort of children with HRNBL on Children's Oncology Group (COG) post-consolidation immunotherapy trials ANBL0032 and ANBL0931 at Pediatric Health Information System (PHIS) centers from 2005 to 2014. Race and ethnicity were categorized to reflect historically marginalized populations as

SUBMITTER: Shoag J 

PROVIDER: S-EPMC11343658 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature